Illumina, Inc.
NASDAQ:ILMNMedical - Diagnostics & Research
+$1.95 today
- Market cap
- $31.75B
- Beta
- 1.49
- P/E (TTM)
- 28.9
- EPS (TTM)
- $5.58
Volume 1.63M
Average 1.65M
ILMN Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Illumina, Inc.NASDAQ: ILMN
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin grows in line with its trailing trend
Q2 FY2026 selling, general & admin of $273M rose 8.3% year over year, ahead of the +7.7% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 0.4% from the prior quarter. Over 3 fiscal years it compounded at -6.0% a year.
Context
- Selling, general & admin amounted to 24.9% of revenue in FY2025, down 0.1 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 14 analysts of $1.48B (+37.5%) for the fiscal year ending Dec 2026, a step up from the -1.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $273M+0.4% QoQ
- Last fiscal yearDec 2025
- $1.08B-1.3% YoY
- LTMJun 2026
- $1.1B+7.7% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 1.08B USD
- Year-over-year change
- -1.3%
- 4-year CAGR
- -15.3%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | 1.08B | -1.3% |
| FY2024 | 2024-12-29 | 1.09B | -32.3% |
| FY2023 | 2023-12-31 | 1.61B | +24.3% |
| FY2022 | 2023-01-01 | 1.3B | -38.0% |
| FY2021 | 2022-01-02 | 2.09B | — |
Selling, General & Admin vs competitors
How ILMN compares with its peers on the latest reported figures
- ILMN's LTM Jun 2026 selling, general & admin of $1.1B is the 2nd highest of the 11 companies compared; the peer median is $294.99M.
- Its year-over-year change of +7.7% is the 7th highest of 11, against a peer median of +21.7%.
- Selling, general & admin amounts to 24.5% of revenue for ILMN, versus a peer median of 64.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.25B | +22.3% | +26.0% | 46.4% | |
| LTM Jun 2026 | $1.1B | +7.7% | -6.0% | 24.5% | |
| LTM Sep 2026 | $951.07M | +44.5% | +15.0% | 74.4% | |
| LTM Mar 2026 | $537.7M | -3.2% | +1.5% | 64.9% | |
| LTM Jun 2026 | $359.09M | +0.6% | +9.5% | 46.9% | |
| LTM Sep 2026 | $297.71M | -10.7% | +2.0% | 48.1% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $292.26M | +58.0% | -10.9% | 64.3% |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $180.71M | +60.0% | — | 45.5% |
| LTM Mar 2026 | $132.48M | -17.6% | -4.2% | 82.8% | |
| LTM Mar 2026 | $91.67M | +21.1% | +0.4% | 112.9% | |
| LTM Mar 2026 | $59.21M | +26.4% | -5.7% | 91.8% | |
| Peer median (excluding ILMN) | $294.99M | +21.7% | +1.5% | 64.6% | |
Competitors are the stored peer set for ILMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.53B | 4.58B | 4.5B | 4.37B | 4.34B |
| Cost of Revenue | 1.37B | 1.61B | 1.76B | 1.51B | 1.45B |
| Gross Profit | 3.15B | 2.97B | 2.74B | 2.86B | 2.89B |
| Gross Margin | 69.7% | 64.8% | 60.9% | 65.4% | 66.7% |
| Research & Development | 1.19B | 1.32B | 1.35B | 1.17B | 951M |
| Selling, General & Admin | 2.09B | 1.3B | 1.61B | 1.09B | 1.08B |
| Operating Expenses | 3.28B | 7.15B | 3.81B | 3.69B | 2.03B |
| Depreciation & Amortization | 251M | 394M | 432M | 354M | 270M |
| EBITDA | 1.2B | (3.92B) | (608M) | (725M) | 1.46B |
| EBITDA Margin | 26.4% | -85.4% | -13.5% | -16.6% | 33.6% |
| Operating Income | (123M) | (4.18B) | (1.07B) | (833M) | 864M |
| Operating Margin | -2.7% | -91.2% | -23.7% | -19.1% | 19.9% |
| Interest Income | 0 | 11M | 58M | 46M | 40M |
| Interest Expense | 61M | 26M | 77M | 100M | 101M |
| Other Income / Expenses | 1.01B | (157M) | (48M) | (346M) | 222M |
| Income Before Tax | 884M | (4.34B) | (1.12B) | (1.18B) | 1.09B |
| Pre-Tax Margin | 19.5% | -94.6% | -24.8% | -27.0% | 25.0% |
| Income Tax Expense | 122M | 68M | 44M | 44M | 236M |
| Net Income | 762M | (4.4B) | (1.16B) | (1.22B) | 850M |
| Net Margin | 16.8% | -96.1% | -25.8% | -28.0% | 19.6% |
| EPS (Basic) | 5.08 | (28.05) | (7.35) | (7.69) | 5.48 |
| EPS (Diluted) | 5.05 | (28.05) | (7.35) | (7.69) | 5.45 |
| Weighted Avg Shares | 150M | 157M | 158M | 159M | 155M |
| Weighted Avg Shares (Diluted) | 151M | 157M | 158M | 159M | 156M |
Illumina, Inc.
NASDAQ:ILMN
Intrinsic Alpha fair value
Locked
Current Price
$210.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.